Cargando…

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections

OBJECTIVES: Cystic fibrosis (CF) patients are often colonized with Pseudomonas aeruginosa. During treatment, P. aeruginosa can develop subpopulations exhibiting variable in vitro antimicrobial (ABX) susceptibility patterns. Heteroresistance (HR) may underlie reported discrepancies between in vitro s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monogue, Marguerite L, Sanders, James M, Pybus, Christine A, Kim, Jiwoong, Zhan, Xiaowei, Clark, Andrew E, Greenberg, David E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333726/ https://www.ncbi.nlm.nih.gov/pubmed/37441352 http://dx.doi.org/10.1093/jacamr/dlad083

Ejemplares similares

1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
por: Sanders, James, et al.
Publicado: (2021)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
por: Garazzino, Silvia, et al.
Publicado: (2020)

2253. Comparison of Outcomes Between Patients with and without Cystic Fibrosis Treated with Ceftolozane–Tazobactam for Pseudomonas aeruginosa Infections
por: Trisler, Michael J, et al.
Publicado: (2019)

Time–Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients
por: Rac, Hana, et al.
Publicado: (2017)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

1587. Comparative In Vitro Antipseudomonal Activity of Ceftolozane/Tazobactam Against Pseudomonas aeruginosa Isolates from Children with Cystic Fibrosis
por: Kanwar, Neena, et al.
Publicado: (2019)

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients
por: Sader, Helio S, et al.
Publicado: (2021)

In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients
por: Dassner, Aimee M., et al.
Publicado: (2016)

Ceftolozane/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa
por: Romano, Meredith Tate, et al.
Publicado: (2020)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency
por: Stokem, Katie, et al.
Publicado: (2017)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients
por: Coppola, Paolo E., et al.
Publicado: (2020)

1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against Pseudomonas aeruginosa (PSA) from Patients with Cystic Fibrosis (CF)
por: Lasko, Maxwell J, et al.
Publicado: (2020)

415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014)

292. Ceftolozane/Tazobactam for Treatment of Osteomyelitis due to Multi-Drug-Resistant Pseudomonas aeruginosa
por: Gerlach, Anthony, et al.
Publicado: (2018)

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
por: Gallagher, Jason C, et al.
Publicado: (2018)

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

349. Hardware-Associated Multidrug-resistant Pseudomonas aeruginosa Meningitis Treated with Ceftolozane-Tazobactam
por: Li, Caitlin, et al.
Publicado: (2020)

Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
por: Gangcuangco, Louie Mar, et al.
Publicado: (2016)

Experience With Ceftolozane-Tazobactam for the Treatment of Serious Pseudomonas aeruginosa Infections in Saudi Tertiary Care Center
por: Bosaeed, M, et al.
Publicado: (2020)

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates
por: Forrester, Jeanne B, et al.
Publicado: (2018)

Activity of Ceftolozane-Tazobactam Against Global Pseudomonas Aeruginosa and Non-Susceptible Phenotypes: SMART 2016
por: Lob, Sibylle, et al.
Publicado: (2017)

Ceftolozane-Tazobactam Resistance in Multidrug-Resistant Pseudomonas aeruginosa Isolates Not Associated with AmpC Activity
por: Tran, Truc T, et al.
Publicado: (2017)

Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam
por: Monterrubio-Villar, Jesús, et al.
Publicado: (2018)

1592. In Vitro Activity of Ceftolozane/Tazobactam (C/T) Against Enterobacteriaceae and Pseudomonas aeruginosa Circulating in Chile
por: Rivas, Lina M, et al.
Publicado: (2019)

Use of Ceftolozane-Tazobactam in Patient with Severe Medium Chronic Purulent Otitis by XDR Pseudomonas aeruginosa
por: Saraca, L. M., et al.
Publicado: (2019)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
por: Nasomsong, Worapong, et al.
Publicado: (2022)

Stewardship Nightmare: Ceftolozane/Tazobactam–Resistant Pseudomonas aeruginosa Infections Accelerated by the COVID-19 Pandemic
por: Haviland, Adam, et al.
Publicado: (2021)

1594. Ceftolozane–Tazobactam Demonstrates Higher In Vitro Susceptibility than Ceftazidime–Avibactam Against Pseudomonas aeruginosa Isolated from Respiratory Tract of Adult Cystic Fibrosis Patients
por: Nolan, Patrick James, et al.
Publicado: (2019)

A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Hart, Delaney E, et al.
Publicado: (2021)

1219. Unfavorable Clinical Outcomes with Polymyxins Compared to Ceftolozane/Tazobactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients
por: Marner, Michael, et al.
Publicado: (2023)

Mechanisms of Heteroresistance and Resistance to Imipenem in Pseudomonas aeruginosa
por: Xu, Ye, et al.
Publicado: (2020)

Quorum sensing regulates heteroresistance in Pseudomonas aeruginosa
por: Lu, Yang, et al.
Publicado: (2022)

2812. Clinical Impact of the Ceftolozane-Tazobactam Shortage on Difficult-To-Treat Resistant Pseudomonas aeruginosa Infections at an Academic Medical Center
por: Vance, Mary K, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ub7n50ernp1ecnkf0bs1ng8jlm